Recent Updates
Recently added Catalysts

Rimexolone

Phase 3

Dry Eye | Small molecule | Ophthalmology |Alcon Inc.|Last Updated: Jun 5, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment750
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00471419Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry EyePHASE3 COMPLETED 750 — — Jul 1, 2006Aug 1, 2007Jun 5, 20121 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Corneal staining; dry eye sympton
Immediate
Secondary Endpoints
Corneal staining; dry eye sympton
Prolonged
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
RimexoloneDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * documented dry eye history * ocular symptoms * tear use * dry eye ocular signs Exclusion Criteria: * Under 18

Countries:United States
Unlock Eligibility Criteria